Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Zhang, Xiao-Hui  [Clear All Filters]
2022
Li S-Q, Xu L, Wang Y, Zhang X-H, Chen H, Chen Y-H, Wang F-R, Han W, Sun Y-Q, Yan C-H, et al. Complement of an LSC-based MRD assay to the traditional MFC method for relapse prediction of AML: a prospective study. Blood. 2022.
Xu L-P, Lu D-P, Wu D-P, Jiang E-L, Liu D-H, Huang H, Sun Z-M, Li N-N, Liu Q-F, Zhang X, et al. Hematopoietic stem cell transplantation activity in China 2020-2021 during the SARS-CoV-2 pandemic: a report from the Chinese Blood and Marrow Transplantation Registry Group. Transplant Cell Ther. 2022.
Tian L, Zhang X-H, Xu K, Li Y. Induced pluripotent stem cell line BIOi003-A from a patient with ABCA4-associated retinal dystrophy carrying compound heterozygous c.(1222C>T;2919-884G>T) variants in ABCA4. Stem Cell Res. 2022;64:102894.
Deng R-X, Zhu X-L, Zhang A-B, He Y, Fu H-X, Wang F-R, Mo X-D, Wang Y, Zhao X-Y, Zhang Y-Y, et al. Machine learning algorithm as a prognostic tool for venous thromboembolism in allogeneic transplant patients. Transplant Cell Ther. 2022.
Luo X-Y, Kong Y, Lv M, Mo X-D, Wang Y, Xu L-P, Zhang X-H, Huang X-J, Tang F-F. The nuclear factor erythroid 2-related factor 2 agonist tert-butylhydroquinone improves bone marrow mesenchymal stromal cell function in prolonged isolated thrombocytopenia after allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2022.
Chen H, Xu L-P, Zhang X-H, Wang Y, Chen Y-H, Yan C-H, Cheng Y-F, Han W, Chen Y, Qin Y-Z, et al. Safety and outcomes of maintenance therapy with third-generation tyrosine kinase inhibitor after allogeneic hematopoietic cell transplantation in Philadelphia chromosome positive acute lymphoblastic leukemia patients with T315I mutation. Leuk Res. 2022;121:106930.
2021
Huang Q-S, Liu Y, Wang J-B, Peng J, Hou M, Liu H, Feng R, Wang J-W, Xu L-P, Wang Y, et al. All-trans retinoic acid plus high-dose dexamethasone as first-line treatment for patients with newly diagnosed immune thrombocytopenia: a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Haematol. 2021;8(10):e688-e699.
Xu L-P, Yu Y, Cheng Y-F, Zhang Y-Y, Mo X-D, Han T-T, Wang F-R, Yan C-H, Sun Y-Q, Chen Y-H, et al. Development and validation of a mortality predicting scoring system for severe aplastic anaemia patients receiving haploidentical allogeneic transplantation. Br J Haematol. 2021.
Zhang X-H, Xie Y, Xu K, Li Y. Generation of an induced pluripotent stem cell line BIOi002-A from a patient with autosomal dominant optic atrophy. Stem Cell Res. 2021;53:102278.
Sun Y-Q, Xu L-P, Liu K-Y, Zhang X-H, Yan C-H, Jin J, Huang X-J, Wang Y. Pre-transplantation cytoreduction does not benefit advanced myelodysplastic syndrome patients after myeloablative transplantation with grafts from family donors. Cancer Commun (Lond). 2021.
Zhao P, Wu Y, He Y, Chong S, Qu Q, Deng R, Sun X, Huang Q-S, Liu X, Zhu X, et al. A prognostic model (BATAP) with external validation for patients with transplant-associated thrombotic microangiopathy. Blood Adv. 2021.
Cao L-Q, Zhou J-R, Zhang X-H, Xu L-P, Wang Y, Chen Y-H, Chen H, Chen Y, Han W, Yan C-H, et al. A scoring system for predicting the prognosis of late-onset severe pneumonia after allogeneic hematopoietic stem cell transplantation. Transplant Cell Ther. 2021.
Wang J-Z, Huang X-J, Zhang Y-Y, Tang F-F, Han T-T, Mo X-D, Sun Y-Q, Chen Y-H, Wang Y, Zhang X-H, et al. Successful hematopoietic stem cell transplantation with haploidentical donors and non-irradiation conditioning in patients with Fanconi anemia. Chin Med J (Engl). 2021;134(20):2518-2520.
2020
Tang F-F, Cheng Y-F, Xu L-P, Zhang X-H, Yan C-H, Han W, Chen Y-H, Huang X-J, Wang Y. cGVHD in pediatric haplo-HSCT. Biol Blood Marrow Transplant. 2020.
Zhang J-M, Xu Y, Gale RP, Wu L-X, Zhang J, Feng Y-H, Qin Y-Z, Jiang H, Jiang Q, Jiang B, et al. DPEP1 expression promotes proliferation and survival of leukaemia cells and correlates with relapse in adults with common B cell acute lymphoblastic leukaemia. Br J Haematol. 2020.
Zeng Q-Z, Zhang Y-Y, Wu Y-J, Zhang Z-Y, Zhang J-N, Fu H-X, Wang J-Z, Wang F-R, Yan C-H, Mo X-D, et al. Frequency, risk factors and outcome of active tuberculosis following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2020.
Han T-T, Zhang Y-N, Sun Y-Q, Kong J, Wang F-R, Wang Z-D, Cheng Y-F, Yan C-H, Wang Y, Xu L-P, et al. Human herpesvirus 6 reactivation in unmanipulated haploidentical hematopoietic stem cell transplantation predicts the occurrence of grade II to IV acute graft-versus-host disease. Transpl Infect Dis. 2020:e13544.
Liu J, Gao H, Xu L-P, Mo X-D, Liu R, Liang S, Wu N, Wang M, Wang Z, Chang Y-J, et al. Immunosuppressant indulges EBV reactivation and related lymphoproliferative disease by inhibiting Vδ2 T cells activities after hematopoietic transplantation for blood malignancies. J Immunother Cancer. 2020;8(1).
Xu Z-L, Cheng Y-F, Zhang Y-Y, Mo X-D, Han T-T, Wang F-R, Yan C-H, Sun Y-Q, Chen Y-H, Tang F-F, et al. The incidence, clinical outcome and protective factors of mixed chimerism following hematopoietic stem cell transplantation for severe aplastic anemia. Clin Transplant. 2020:e14160.
Tang F-F, Cheng Y-F, Xu L-P, Zhang X-H, Yan C-H, Han W, Chen Y-H, Huang X-J, Wang Y. The incidence, risk factors, and outcomes of acute graft-vs-host disease in pediatric T-cell-replete haploidentical hematopoietic stem cell transplantation. Pediatr Transplant. 2020:e13793.
Tang F-F, Sun Y-Q, Mo X-D, Lv M, Chen Y-H, Wang Y, Xu L-P, Zhang X-H, Huang X-J. The incidence, risk factors, and outcomes of primary prolonged isolated thrombocytopenia after haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2020.
Chen Q, Zhao X, Fu H-X, Chen Y-H, Zhang Y-Y, Wang J-Z, Wang Y, Wang F-R, Mo X-D, Han W, et al. Posterior reversible encephalopathy syndrome (PRES) after haploidentical haematopoietic stem cell transplantation: incidence, risk factors and outcomes. Bone Marrow Transplant. 2020.
Liu S-N, Zhang X-H, Xu L-P, Wang Y, Yan C-H, Chen H, Chen Y-H, Han W, Wang F-R, Wang J-Z, et al. Prognostic factors and long-term follow-up of basiliximab for steroid-refractory acute GVHD: updated experienced from a large-scale study. Am J Hematol. 2020.

Pages